Introduction: Radionuclide therapy in the form of 131I-MIBG has been in therapeutic use since the 1980s. Newer modalities are emerging for the treatment of neuroendocrine and chromaffin cell tumors, but many of these do not yet have adequate long-term follow-up to determine longer term efficacy and sequelae.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr Wing-Chiu C Sze